Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275431 | 1.00 | PDE3B (0.33) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10275691 | 0.89 | PDE3B (0.35) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10276214 | 0.89 | PDE3B (0.35) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10275785 | 0.86 | ALOX5AP (0.34) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10275787 | 0.86 | ALOX5AP (0.34) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10276138 | 0.85 | KDM1A (0.38) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10276297 | 0.85 | KDM1A (0.34) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10276141 | 0.85 | KDM1A (0.38) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10276298 | 0.85 | KDM1A (0.34) | PDE3BPDE3AKDM1AARALOX5AP | |
| SCHEMBL10275577 | 0.83 | PDE3B (0.35) | PDE3BPDE3AKDM1AARALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PDE3B 2361/4885PDE3A 2182/4885KDM1A 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.